Avitotamig Biosimilar – Anti-Myeloid cell surface antigen CD33 mAb – Research Grade from ProteoGenix; catalogue PX-TA2172; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Avitotamig Biosimilar – Anti-Myeloid cell surface antigen CD33 mAb is a therapeutic antibody that has been developed as a biosimilar to the existing anti-CD33 monoclonal antibody (mAb) therapies. This biosimilar is designed to target the myeloid cell surface antigen CD33, which is overexpressed in various hematological malignancies, making it a promising therapeutic target.
Avitotamig Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the CD33 antigen, while the constant region is involved in effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Avitotamig Biosimilar binds specifically to the CD33 antigen on the surface of myeloid cells, leading to the activation of immune effector mechanisms. This results in the destruction of CD33-expressing cells, including leukemic cells, through ADCC and CDC. Additionally, Avitotamig Biosimilar has been shown to induce apoptosis in CD33-positive cells, further contributing to its anti-tumor activity.
Avitotamig Biosimilar is currently being investigated for its potential use in the treatment of various hematological malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL). It has also shown promising results in preclinical studies for the treatment of solid tumors, such as breast cancer and lung cancer, which have been found to express CD33.
Avitotamig Biosimilar is a therapeutic antibody that has been developed as a biosimilar to the existing anti-CD33 mAb therapies. As a biosimilar, it has been rigorously tested to demonstrate similarity to the reference product in terms of structure, activity, and clinical efficacy. This ensures that Avitotamig Biosimilar is a safe and effective alternative to the reference product, providing patients with more options for treatment.
The myeloid cell surface antigen CD33 is a glycoprotein that is expressed on the surface of myeloid cells, including AML blasts, monocytes, and dendritic cells. It is involved in cell signaling and plays a role in the regulation of myeloid cell proliferation and differentiation. Overexpression of CD33 has been observed in various hematological malignancies, making it a promising therapeutic target for the treatment of these diseases.
Avitotamig Biosimilar is currently in the research and development phase, with preclinical and clinical studies being conducted to evaluate its safety and efficacy. As a research grade product, it is not yet approved for clinical use, but is being used in laboratory studies to gather data on its potential as a therapeutic agent. The results of these studies will inform the future development and potential approval of Avitotamig Biosimilar for clinical use.
In summary, Avitotamig Biosimilar – Anti-Myeloid cell surface antigen CD33 mAb is a promising therapeutic antibody that targets the CD33 antigen on myeloid cells. Its unique structure and mechanism of action make it a potential treatment option for various hematological malignancies. As a biosimilar, it offers patients a safe and effective alternative to existing anti-CD33 mAb therapies.
ProteoGenix catalogue number PX-TA2172. For research use only.
Target: Avitotamig Biosimilar – Anti-Myeloid cell surface antigen CD33 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Avitotamig Biosimilar – Anti-Myeloid cell surface antigen CD33 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
